share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股sec公告 ·  04/16 16:42
Moomoo AI 已提取核心信息
Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol ADIL, has filed a Form 8-K with the United States Securities and Exchange Commission on April 10, 2024. The report announces the termination of the consulting agreement with Dr. Bankole A. Johnson, who has served as the company's Chief Medical Officer. The agreement, which began on March 24, 2019, and was amended on March 22, 2022, and September 8, 2022, will be effectively terminated on May 17, 2024. Following this date, Dr. Johnson will no longer hold the position of Chief Medical Officer at Adial Pharmaceuticals. The company has fulfilled the SEC's requirements by having the report signed by President and Chief Executive Officer Cary J. Claiborne.
Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol ADIL, has filed a Form 8-K with the United States Securities and Exchange Commission on April 10, 2024. The report announces the termination of the consulting agreement with Dr. Bankole A. Johnson, who has served as the company's Chief Medical Officer. The agreement, which began on March 24, 2019, and was amended on March 22, 2022, and September 8, 2022, will be effectively terminated on May 17, 2024. Following this date, Dr. Johnson will no longer hold the position of Chief Medical Officer at Adial Pharmaceuticals. The company has fulfilled the SEC's requirements by having the report signed by President and Chief Executive Officer Cary J. Claiborne.
Adial Pharmicals, Inc. 是一家在纳斯达克资本市场上市的特拉华州注册公司,交易代码为ADIL,该公司已于2024年4月10日向美国证券交易委员会提交了8-K表格。该报告宣布终止与曾担任公司首席医疗官的班科尔·约翰逊博士的咨询协议。该协议于2019年3月24日开始,于2022年3月22日和2022年9月8日进行了修订,将于2024年5月17日有效终止。此后,约翰逊博士将不再在Adial Pharmicals担任首席医学官一职。该公司由总裁兼首席执行官卡里·克莱伯恩签署了报告,从而满足了美国证券交易委员会的要求。
Adial Pharmicals, Inc. 是一家在纳斯达克资本市场上市的特拉华州注册公司,交易代码为ADIL,该公司已于2024年4月10日向美国证券交易委员会提交了8-K表格。该报告宣布终止与曾担任公司首席医疗官的班科尔·约翰逊博士的咨询协议。该协议于2019年3月24日开始,于2022年3月22日和2022年9月8日进行了修订,将于2024年5月17日有效终止。此后,约翰逊博士将不再在Adial Pharmicals担任首席医学官一职。该公司由总裁兼首席执行官卡里·克莱伯恩签署了报告,从而满足了美国证券交易委员会的要求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息